ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly shares available for future grant under equity compensation plans (millions) (M)
Form 10-K Stock-Based Compensation Note
Latest, FY2025
42.4
Period ended Dec 31, 2025
Change on a year earlier
-13.1%
48.8 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Shares available for future grant under equity compensation plans (millions) (M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.4 | -13.1% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 48.8 | -0.6% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 49.1 | -1.8% | Form 10-K (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 50 | -1.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 50.6 | -6.1% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 53.9 | -1.3% | Form 10-K (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 54.6 | +2.4% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 53.3 | -45.8% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 98.3 | -1.3% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 99.6 | – | Form 10-K (filed 2017-02-21) ↗ |
Cite this data
StockData. (2026). Eli Lilly Shares available for future grant under equity compensation plans (millions) (M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/sbc_shares_avail
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.